Takeda abandons one of its top experimental drugs following a slap down at the FDA
Takeda has abandoned one of the drugs that had once sat at the top of its list of first- or best-in-class drug hopefuls.
Just weeks after a largely unexplained CRL on the drug, the global pharma player noted in its quarterly update today that it has dropped TAK-721, which was once slated to hit the market this year as Eohilia.
Better known as budesonide oral suspension, picked up in its big $62 billion Shire buyout, Takeda had heralded the therapy for eosinophilic esophagitis, which had picked up a priority review. But instead of a quick OK and an advancement to the “best (or first) in class” future that Takeda execs had expected, the agency delayed their decision and followed up with a formal rejection in December.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
